One-Year Outcomes After Treatment of Ostial In-Stent Restenosis in Left Circumflex Versus Left Anterior Descending or Right Coronary Artery.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 07 2021
Historique:
received: 05 01 2021
revised: 16 03 2021
accepted: 22 03 2021
pubmed: 26 5 2021
medline: 14 9 2021
entrez: 25 5 2021
Statut: ppublish

Résumé

The prognosis of left circumflex (LC) versus non-LC in-stent restenosis (ISR) ostial lesions following treatment has not been assessed. We aimed to assess this prognosis. Anecdotally, treatment of ostial LC ISR has been associated with high recurrence rates. We performed a retrospective analysis of patients from our institution who underwent coronary intervention of an ostial ISR lesion between 2003 and 2018. The primary endpoint was target lesion revascularization (TLR) and major adverse cardiovascular events (MACE). Overall, 563 patients underwent ostial ISR lesion intervention, 144 for an ostial LC ISR lesion. Compared to patients with ostial ISR in non-LC lesions, patients with ostial LC ISR were older, had higher rates of diabetes mellitus and previous coronary bypass surgery. At 1-year follow-up, TLR-MACE rates were 26.6% in the LC group versus 18.4% in the non-LC group (p = 0.036). The TLR rate was also higher in the LC group compared to the non-LC group (p = 0.0498). Univariate and multivariate analyses demonstrated a higher TLR-MACE rate for LC versus non-LC ostial ISR lesions. In conclusion, our study shows increased event rates after treatment of LC versus non-LC ISR lesions. Further studies should be done to assess the optimal treatment approach for ostial LC ISR.

Identifiants

pubmed: 34030883
pii: S0002-9149(21)00315-5
doi: 10.1016/j.amjcard.2021.03.045
pii:
doi:

Substances chimiques

Metals 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

45-50

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Auteurs

Chava Chezar-Azerrad (C)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Anees Musallam (A)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Corey Shea (C)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Cheng Zhang (C)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Rebecca Torguson (R)

The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

Charan Yerasi (C)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Brian C Case (BC)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Brian J Forrestal (BJ)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Nauman Khalid (N)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Jaffar M Khan (JM)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia; Cardiovascular Branch, Division of Intramural Research, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland.

Evan Shlofmitz (E)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Yuefeng Chen (Y)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Lowell F Satler (LF)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Nelson L Bernardo (NL)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Itsik Ben-Dor (I)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Toby Rogers (T)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia; Cardiovascular Branch, Division of Intramural Research, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland.

Hayder Hashim (H)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Gary S Mintz (GS)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Ron Waksman (R)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia. Electronic address: Ron.Waksman@medstar.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH